Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.65 |
| ▸ | ACHE | P22303 | 5/20 | 0.55 |
| ▸ | MAOB | P27338 | 4/20 | 0.55 |
| ▸ | MAOA | P21397 | 1/20 | 0.54 |
| ▸ | KDM4A | O75164 | 2/20 | 0.52 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.52 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.51 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.51 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.51 |
| ▸ | HTR7 | P34969 | 2/20 | 0.50 |
| ▸ | APP | P05067 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24504977 | 0.98 | SIGMAR1 (0.62) | SIGMAR1ACHEMAOBMAOAKDM4A | |
| SCHEMBL7937668 | 0.86 | CARM1 (0.58) | SIGMAR1ACHEMAOBMAOACARM1 | |
| SCHEMBL29733117 | 0.86 | SIGMAR1 (0.85) | SIGMAR1ACHEMAOBMAOAKDM4A | |
| SCHEMBL7225346 | 0.86 | SIGMAR1 (0.85) | SIGMAR1ACHEMAOBMAOAKDM4A | |
| SCHEMBL15362878 | 0.83 | SIGMAR1 (0.65) | SIGMAR1ACHEMAOBMAOAKDM4A | |
| SCHEMBL15336537 | 0.83 | SIGMAR1 (0.65) | SIGMAR1ACHEMAOBMAOAKDM4A | |
| SCHEMBL1449848 | 0.83 | HDAC3 (0.54) | SIGMAR1ACHEMAOB | |
| SCHEMBL1449161 | 0.83 | HDAC3 (0.54) | SIGMAR1ACHEMAOB | |
| SCHEMBL4330336 | 0.81 | HDAC3 (0.53) | ACHEMAOB | |
| SCHEMBL9136021 | 0.81 | SIGMAR1 (0.61) | SIGMAR1ACHEMAOBMAOAKDM4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3221293-B1 | IONIZABLE CATIONIC LIPID FOR RNA DELIVERY | ARCTURUS THERAPEUTICS INC (US) | 2023-03-01 | — | — | EP | disclosed |
| US-7638639-B2 | Substituted pyrrolidine and related compounds | THERAVANCE, INC. (US) | 2009-12-29 | — | — | US | disclosed |
| US-7615566-B2 | Substituted pyrrolidine and related compounds | THERAVANCE, INC. (US) | 2009-11-10 | — | — | US | disclosed |
| US-7524880-B2 | Crystalline form of a substituted pyrrolidine compound | THERAVANCE, INC. (US) | 2009-04-28 | — | — | US | disclosed |
| US-20080161577-A1 | Substituted pyrrolidine and related compounds | THERAVANCE BIOPHARMA R&D IP, LLC | 2008-07-03 | — | — | US | disclosed |
| US-20080146649-A1 | Substituted pyrrolidine and related compounds | THERAVANCE BIOPHARMA R&D IP, LLC | 2008-06-19 | — | — | US | disclosed |
| US-7351718-B2 | Substituted pyrrolidine and related compounds | THERAVANCE, INC. (US) | 2008-04-01 | — | — | US | disclosed |
| US-7351717-B2 | Substituted pyrrolidine and related compounds | THERAVANCE, INC. (US) | 2008-04-01 | — | — | US | disclosed |
| US-20070135482-A1 | Substituted pyrrolidine and related compounds | THERAVANCE BIOPHARMA R&D IP, LLC | 2007-06-14 | — | — | US | disclosed |
| US-20070078163-A1 | Substituted pyrrolidine and related compounds | THERAVANCE BIOPHARMA R&D IP, LLC | 2007-04-05 | — | — | US | disclosed |
| US-7183292-B2 | Substituted pyrrolidine and related compounds | THERAVANCE, INC. (US) | 2007-02-27 | — | — | US | disclosed |
| US-20050277688-A1 | Crystalline form of a substituted pyrrolidine compound | THERAVANCE, INC. | 2005-12-15 | — | — | US | disclosed |
| US-20040254219-A1 | Substituted pyrrolidine and related compounds | THERAVANCE BIOPHARMA R&D IP, LLC | 2004-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135482-A1 | Substituted pyrrolidine and related compounds | CHRM1, CHRM5, CHRM2 | SIGMAR1 264/4885ACHE 288/4885MAOB 572/4885 |
| US-20050277688-A1 | Crystalline form of a substituted pyrrolidine compound | PKD2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, PKD1 | SIGMAR1 1865/4885ACHE 4701/4885MAOB 4706/4885 |
| US-20080161577-A1 | Substituted pyrrolidine and related compounds | CHRM1, CHRM5, CHRM2 | SIGMAR1 264/4885ACHE 288/4885MAOB 572/4885 |
| US-20040254219-A1 | Substituted pyrrolidine and related compounds | CHRM1, CHRM5, ADRA1D | SIGMAR1 151/4885ACHE 388/4885MAOB 961/4885 |
| US-20080146649-A1 | Substituted pyrrolidine and related compounds | CHRM1, CHRM5, CHRM2 | SIGMAR1 264/4885ACHE 288/4885MAOB 572/4885 |
| US-20070078163-A1 | Substituted pyrrolidine and related compounds | CHRM1, CHRM5, CHRM2 | SIGMAR1 264/4885ACHE 288/4885MAOB 572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.